Welcome to our dedicated page for Immix Biopharma SEC filings (Ticker: IMMX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Immix Biopharma, Inc. filings document a Nasdaq-listed clinical-stage biopharmaceutical company with common stock registered under ticker IMMX and a development program centered on NXC-201 for relapsed/refractory AL Amyloidosis. Current reports include Regulation FD and other-event disclosures for NEXICART-2 clinical updates and regulatory-development matters.
The company’s SEC record also covers capital-structure activity, including at-the-market sales agreements, shelf registration statements, registered offerings, private placements, warrants and resale registration rights. Proxy materials disclose director elections, auditor ratification, annual-meeting voting results and other governance matters.
Immix Biopharma, Inc. (IMMX) filed a current report to update the audit firm consents tied to its existing shelf registration. The company obtained new consents dated November 26, 2025 from KMJ Corbin & Company LLP, its former independent registered public accounting firm, and Crowe LLP, its current independent registered public accounting firm. These consents allow the firms’ audit reports dated March 29, 2024 and March 24, 2025 on Immix Biopharma’s consolidated financial statements in its Annual Report on Form 10-K for the year ended December 31, 2024 to be incorporated by reference into the company’s effective Form S-3 registration statement (No. 333-290725) and referenced under the “Experts” section of the related prospectus. The filing does not announce new operating results or business transactions and is primarily an administrative update supporting ongoing use of the existing registration statement.
Immix Biopharma reported third-quarter 2025 results, highlighting continued R&D investment and financing activity alongside a going concern warning. The company posted a net loss of $7,585,692 for Q3 and $18,750,783 for the nine months ended September 30, 2025. Operating expenses were $7,662,509 in Q3, driven by R&D $4,584,131 and G&A $3,078,378.
Liquidity remained constrained with cash and cash equivalents of $15,947,308 at quarter-end and operating cash use of $12,900,697 year-to-date. Management stated there is substantial doubt about the company’s ability to continue as a going concern over the next twelve months.
To fund operations, Immix raised capital via a private placement of 3,915,604 shares and 2,936,709 warrants at a combined price of $2.37, yielding ~$9.3 million gross, and through an ATM program that delivered net proceeds of $2,573,375 for the nine months. The CIRM grant award totals $8 million, with ~$4.6 million received to date and ~$3.4 million remaining subject to milestones. Shares outstanding were 33,577,873 as of November 5, 2025.
Immix Biopharma, Inc. (IMMX) filed a shelf registration on Form S-3 that includes a prospectus outline and an exhibit and security-holder table showing current beneficial holders and share counts as of October 2, 2025. Several institutional and individual holders are listed with specific share totals (examples: Nancy T. Chang 1,551,790 total shares, Robinhood II, LP 813,395 total shares). The document discloses legal and accounting offering-related expenses of $20,000 each and total offering costs of $46,977. Indemnification provisions under the amended charter and bylaws are noted, including advancement of expenses to indemnitees with potential reimbursement if not entitled under applicable law.
The filing references incorporated reports (annual and quarterly reports and proxies) and multiple exhibits and signatures by officers and directors dated October 3, 2025. The record is fragmented and appears to be an excerpt focusing on holders, fees, exhibits, and governance indemnities rather than full offering terms or offering size.
Immix Biopharma insider purchase by CEO/Chairman — This Form 4 shows that Ilya M. Rachman, who is identified as a director and as the CEO and Chairman of Immix Biopharma, Inc. (IMMX), purchased 2,500 shares of the company on 09/17/2025 at a volume-weighted average price of $2.02 per share. After the purchase, the filing reports that Mr. Rachman beneficially owned 1,140,937 shares. The filing includes an explanation that the $2.02 VWAP reflects purchases executed at prices ranging from $2.01 to $2.02 and offers to provide transaction-level detail on request. The form is signed by the reporting person on 09/17/2025.
Immix Biopharma insider purchase by CEO/Chairman — This Form 4 shows that Ilya M. Rachman, who is identified as a director and as the CEO and Chairman of Immix Biopharma, Inc. (IMMX), purchased 2,500 shares of the company on 09/17/2025 at a volume-weighted average price of $2.02 per share. After the purchase, the filing reports that Mr. Rachman beneficially owned 1,140,937 shares. The filing includes an explanation that the $2.02 VWAP reflects purchases executed at prices ranging from $2.01 to $2.02 and offers to provide transaction-level detail on request. The form is signed by the reporting person on 09/17/2025.
Immix Biopharma insider purchase: Gabriel Morris, reporting as a Director and CFO, purchased 2,600 shares of Immix Biopharma, Inc. (IMMX) on 09/16/2025 at a price of $1.97 per share. After the transaction he reports 290,659 shares directly beneficially owned and additional indirect holdings of 270,844 shares through Alwaysraise LLC and 24,141 shares through Alwaysraise Ventures/AVILP, with footnotes clarifying his managerial roles and disclaimer of beneficial ownership except for pecuniary interest. The Form 4 is signed by Gabriel Morris on 09/17/2025.
Immix Biopharma insider purchase: Gabriel Morris, reporting as a Director and CFO, purchased 2,600 shares of Immix Biopharma, Inc. (IMMX) on 09/16/2025 at a price of $1.97 per share. After the transaction he reports 290,659 shares directly beneficially owned and additional indirect holdings of 270,844 shares through Alwaysraise LLC and 24,141 shares through Alwaysraise Ventures/AVILP, with footnotes clarifying his managerial roles and disclaimer of beneficial ownership except for pecuniary interest. The Form 4 is signed by Gabriel Morris on 09/17/2025.
Dr. Nancy T. Chang filed an initial Form 3 reporting ownership in Immix Biopharma, Inc. (IMMX) related to a 09/08/2025 event. She is identified as a director and the general manager of Robinhood II, LP. The filing shows 421,940 shares of common stock held directly and 496,940 shares held indirectly by Robinhood II, LP. The report also discloses two non-transferable warrants exercisable on 09/08/2025 and expiring 09/05/2035, each covering 316,455 underlying common shares with a $2 exercise price, listed as one direct and one indirect position. The filer states she may be deemed to beneficially own securities held by Robinhood II, LP but disclaims ownership except to the extent of pecuniary interest. The Form is signed on 09/17/2025.
Immix Biopharma, Inc. filed an 8-K disclosing that on September 5, 2025 it entered into a Securities Purchase Agreement, a Registration Rights Agreement, and issued a form of non-transferable warrant. The filing lists these three exhibits as filed electronically and identifies the report signer as Ilya Rachman, Ph.D., M.D., Chief Executive Officer. No financial terms, purchase amounts, purchaser identities, or timing for registration effectiveness are disclosed in the text provided. The submission indicates these agreements are material events but the document contains only exhibit references, not the underlying pricing, dilution, or use-of-proceeds details.
Immix Biopharma, Inc. reported cash and cash equivalents of $11.6 million at June 30, 2025, down from $17.7 million at year-end, total assets of $15.6 million and total stockholders' equity of $4.65 million. The company recorded a $11.17 million net loss for the six months and operating expenses of $11.4 million over the same period, reflecting continued R&D and G&A spending. Management states it does not have sufficient capital to sustain operations through the next twelve months and discloses substantial doubt about the company’s ability to continue as a going concern.
On the financing and development side, Immix established a $50 million ATM facility and sold 513,935 shares for net proceeds of $1.09 million during the quarter (1,015,347 shares sold for $2.43 million as of August 6, 2025). Clinically, lead candidate NXC-201 has favorable early results: prior cohorts showed overall response rates of 100% (10/10) and 94% (15/16) with complete response rates of 70–75%, and the program holds FDA RMAT and orphan drug designations and an $8 million CIRM grant with $3.6 million received to date.
Immix Biopharma held its 2025 Annual Meeting on June 20, with 72.1% of voting shares represented (20,092,566 shares). Two key proposals were voted upon:
1. Board of Directors Election:
- All eight directors were successfully elected with strong majority support
- Ilya Rachman (CEO), Gabriel Morris, and Jason Hsu received notably high approval rates above 14.3M votes each
- Helen C. Adams and Carey Ng received relatively lower but still substantial support with approximately 13.3-13.6M votes
2. Auditor Appointment:
- Shareholders overwhelmingly approved Crowe LLP as independent auditor for FY2025
- The resolution passed with 19.9M votes in favor (99.3% approval), only 47,622 against, and 98,438 abstentions
The company is classified as an emerging growth company and trades on Nasdaq under symbol IMMX.
Carey Ng, Director of Immix Biopharma (IMMX), reported significant insider trading activity on June 20, 2025. The key transactions include:
- Acquisition of a stock option grant for 33,000 shares with an exercise price of $2.24, expiring June 20, 2035
- The options will vest in 12 equal monthly installments following the grant date, contingent on continued Board service
- Current holdings include 20,000 shares held directly and 1,025,221 shares held indirectly through Mesa Verde Venture Partners III, LP
As Managing Director of Mesa Verde Venture Partners III, LP, Ng has voting and dispositive power over the fund's holdings but disclaims beneficial ownership except for his pecuniary interest. The transaction was executed under a valid Power of Attorney filed previously with the SEC.